Sorafenib, a multikinase inhibitor targeting VEGF signaling as well as several other signaling pathways involved in angiogenesis, was the first systemic therapy approved for the treatment of advanced HCC patients [87,89]. Here, VEGFA is linked to hepatocellular carcinoma.